Clinical Trial Update: Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts [Phase 1, Phase 2]

View source ↗

Summary

This update reports ongoing Phase 1 and Phase 2 clinical evaluation of ABI-2280 vaginal inserts to eradicate high-risk HPV and assess safety, with the trial cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• ABI-2280 vaginal inserts (ABI-2280)

Snippet

Sponsor: Antiva Biosciences | Conditions: Human Papillomavirus Infection | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING